poisar

Stock

Quoin Pharmaceuticals, Ltd. QNRX

$4.28+1.90%

Overview

QNRX market data

Price History

QNRX price chart

Valuation & Profitability

Twelve Data
P/E (TTM)
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
-$14.80
Diluted earnings per share over the trailing twelve months.
Beta
1.48
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$3.25 – $41.80
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $8.4 · P/B 0.61.

Company News

8 captured
Quoin Pharmaceuticals Receives FDA Clearance Of Its Investigational New Drug Application For QRX003 To Treat Peeling Skin SyndromeBenzinga · Jul 9, 2026, 12:40 PM
Quoin Pharmaceuticals Issued Notice Of Allowance From U.S. Patent And Trademark Office Titled Combination Treatment For Netherton SyndromeBenzinga · Jun 30, 2026, 12:35 PM
8-K filing — Quoin Pharmaceuticals, Ltd. (QNRX)SEC EDGAR · Jun 23, 2026, 8:15 PM
Quoin Pharmaceuticals Receives FDA's Conditional Approval For QYLEKI To Treat Netherton SyndromeBenzinga · Jun 23, 2026, 12:40 PM
Quoin Pharmaceuticals Establishes Japanese Subsidiary To Commercialize QRX003 For The Treatment Of Netherton Syndrome Upon Approval By AuthoritiesBenzinga · Jun 18, 2026, 12:45 PM
Quoin Pharmaceuticals Announces That Four Of Six Children In Its Ongoing Pediatric Netherton Syndrome Compassionate Use Study Were Classified As 'Improved' Or 'Significantly Improved' From Baseline Across Key Clinical EndpointsBenzinga · Jun 16, 2026, 12:40 PM
Quoin Pharmaceuticals QRX003 Receives Japan's Ministry Of Health, Labour And Welfare To Treat Netherton SyndromeBenzinga · Jun 4, 2026, 12:50 PM
Quoin Pharmaceuticals Pharmaceuticals Submits Investigational New Drug Application To FDA For Phase II Trial Of Peeling Skin Syndrome Treatment QRX003Benzinga · Jun 2, 2026, 12:36 PM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock